XERS Xeris Biopharma Holdings, Inc. stock chart & analysis
Conviction 4HealthcareScan · Fri, Nov 6, 2026Xeris Biopharma Holdings, Inc. (XERS) closed at $15.20 (+16.21%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 82, RS Rating 99, at a 52-week high, +93.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
XERS technical analysis
Trend
XERS is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 57.8% above the 50-day ($9.62) and 99.7% above the 200-day ($7.61). ADX(14) at 36 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 82, in overbought territory. MACD crossed above its signal line one session ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 2.8× its 20-day average. It trades about $34.9M a day on average. ATR(14) is $0.7887, 5.2% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.07) shows accumulation.
Key levels
The chart pattern's support is $9.38 and its resistance $11.37. The 52-week range is $5.25 to $15.21, and price sits at the high. The VWAP anchored at the 52-week high is $14.65, below price.
Performance
XERS returned +41.8% (1 week), +49.1% (1 month), +90.1% (3 months), +132.6% (6 months), +53.9% (1 year), +93.5% (year to date).
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Pharmaceutical Preparations · Listed 2018 · 435 employees
Recent news
- Xeris Biopharma stock hits 52-week high at 12.53 USD By Investing.comInvesting.com India · Thu, Nov 5, 2026
- Xeris Biopharma Holdings Q3 2026 Earnings Call TranscriptBenzinga · Thu, Nov 5, 2026
- Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year HighsStocktwits · Thu, Nov 5, 2026
- Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance · Thu, Nov 5, 2026
- Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance · Thu, Nov 5, 2026
- Xeris Biopharma: Q3 Earnings SnapshotYahoo Finance · Thu, Nov 5, 2026
- Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business HighlightsYahoo Finance · Thu, Nov 5, 2026
- Xeris Biopharma legal chief Hecht sells $255,827 in stockInvesting.com · Thu, Nov 5, 2026
- Xeris Biopharma COO Kevin McCulloch sells $153,487 in shares By Investing.comInvesting.com UK · Thu, Nov 5, 2026
- Insider Steven Pieper Sells 5,000 Shares of Xeris Biopharma Holdings Inc (XERS)GuruFocus · Wed, Nov 4, 2026
Insider activity
SEC Form 4 transactions in XERS · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
McCulloch Kevin See Remarks · Common Stock · 2026-11-05 | Sell | 25K | $312K | 2026-11-05 | 2026-11-06 |
McCulloch Kevin See Remarks · Common Stock · 2026-11-02 | Sell | 15K | $153K | 2026-11-02 | 2026-11-04 |
Pieper Steven See Remarks · Common Stock · 2026-11-02 | Sell | 5K | $51K | 2026-11-02 | 2026-11-04 |
Taddese Menassie Director · Common Stock · 2026-11-02 | Grant | 22.36K | — | 2026-11-02 | 2026-11-04 |
Taddese Menassie Director · Stock Option (Right to Buy) · 2026-11-02 | Grant | 31.5K | $320K | 2026-11-02 | 2026-11-04 |
Hecht Beth See Remarks · Common Stock · 2026-11-02 | Sell | 25K | $256K | 2026-11-02 | 2026-11-04 |
McCulloch Kevin See Remarks · Common Stock · 2026-08-01 | Tax | 21.92K | $177K | 2026-08-01 | 2026-08-21 |
Shannon John Patrick Jr See Remarks · Common Stock · 2026-08-01 | Tax | 36.65K | $296K | 2026-08-01 | 2026-08-21 |
Pieper Steven See Remarks · Common Stock · 2026-08-12 | Sell | 5K | $43K | 2026-08-12 | 2026-08-12 |
Pieper Steven See Remarks · Common Stock · 2026-07-07 | Sell | 27.6K | $235K | 2026-07-07 | 2026-07-07 |
SEC filings
EDGAR filings in XERS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.